# NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma

> **NCT07680699** · — · RECRUITING · sponsor: **AC Camargo Cancer Center** · enrollment: 250 (estimated)

## Conditions studied

- Cutaneous Melanoma

## Interventions

- **OTHER:** Anti-PD1 Therapy Timing

## Key facts

- **NCT ID:** NCT07680699
- **Lead sponsor:** AC Camargo Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-23
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680699, "NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07680699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*